Lymphatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future

Annals of Surgical Oncology

Volumn 8, Issue 9 SUPPL., 2001, Pages 22-28

  Morton, D L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DYE; MELANOMA VACCINE; PROTEIN S 100; TECHNETIUM 99M;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; REPRODUCIBILITY; SENTINEL LYMPH NODE;

CANCER VACCINES; COLORING AGENTS; FORECASTING; HUMANS; LYMPHATIC METASTASIS; MELANOMA; RADIOPHARMACEUTICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0034778751     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Melanotic cancerous disease
2. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic
3. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II)
4. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: Results of surgical treatment in 1,319 patients
5. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results
6. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities
7. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial
8. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
9. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning
10. The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: A preliminary study
11. A rational approach to the surgical management of melanoma
12. S100 protein is present in cultured human malignant melanomas
13. S100 protein: A marker for human malignant melanomas?
14. Occult melanoma in lymph nodes detected by antiserum to S-100 proteins
15. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease
16. Intraoperative lymphatic mapping and selective lymphadenectomy: Technical details of a new procedure for clinical stage I melanoma
17. Technical details of intraoperative lymphatic mapping for early stage melanoma
18. Gamma-probe-guided lymph node localization in malignant melanoma
19. Intraoperative radiolymphoscintigraphy: A useful adjuvant to intraoperative lymphatic mapping and selective lymphadenectomy in patients with clinical stage I melanoma
20. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?
21. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma
22. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins
23. Intraoperative radiolympho-scintigraphy improves sentinel lymph node identification for patients with melanoma
24. Minimal-access surgery for staging of malignant melanoma
25. The orderly progression of melanoma nodal metastases
26. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes
27. Optimal selective sentinel lymph node dissection in primary malignant melanoma
28. Intraoperative identification of sentinel lymph node in patients with malignant melanoma
29. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck
30. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial
31. Molecular staging of malignant melanoma: Correlation with clinical outcome
32. Identification of submicroscopic lymph node metastases in patients with malignant melanoma
33. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma
34. Carbon dye histologically confirms the identity of sentinel nodes in cutaneous melanoma
35. Melanoma vaccines: Current status of clinical trials
36. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
37. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
38. Vaccine therapy for malignant melanoma
39. Active immunotherapy with allogeneic tumor cell vaccines: Present status